TY  - JOUR
AU  - Romero, Ignacio
AU  - Coronado Martín, Pluvio Jesús
AU  - Poveda, Andrés
PY  - 2020
DO  - 10.1016/j.ygyno.2020.09.013
SN  - 1095-6859
UR  - https://hdl.handle.net/20.500.14352/128858
T2  - Gynecologic Oncology
AB  - Objective: Olaparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1, 2, and 3 with potential activity in endometrial cancer (EC).Methods: In this window-of-opportunity trial, women with operable type 1 EC received olaparib oral tablets...
LA  - eng
M2  - 721
PB  - Elsevier
KW  - Corpus uteri cancer
KW  - Endometrioid carcinoma
KW  - Olaparib
KW  - PARP inhibitor
KW  - Type I endometrial carcinoma
TI  - An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study
TY  - journal article
VL  - 159
ER  -